In Brief: Influence, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Influence, Inc.: Firm's Influ-ENT division launches the Repose surgical system for treatment of obstructive sleep apnea and snoring. The minimally invasive chin bone screw system is intended for use in stabilizing the tongue and preventing it from "collapsing back and obstructing the airway passage," Influence states in a Feb. 3 release. Formerly named the Sleep-In, the device was cleared via 510(k) Aug. 25. The launch was delayed until three-month post-treatment sleep study data could be accumulated and compared to pre-treatment data, Influence explains...
You may also be interested in...
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation
As Eli Lilly chief information and digital officer Rau speaks of generative AI models training humans on drug discovery, Bristol Myers Squibb CDTO Meyers of wearables aiding cell therapy and Microsoft Research India MD Rajamani of interoperability no longer being a huge challenge, a discussion at the BioAsia summit highlights a fundamental shift in R&D approaches.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.